Abstract
The concept according to which unique, rare and common sequences may define immunogenicity, immunopathogenicity and immunotolerance, respectively, is graphically illustrated using a melanoma-associatedantigen, Melan-A/Mart-1, as a model. The final picture is consolidated by experimentally validated data from the scientific literature and may represent a concrete prelude to effective immunotherapies exempt from collateral autoimmune reactions.
Keywords: Anti-cancer immunotherapy, autoimmunity, melan-A/Mart-1, immunogenicity, immunopathogenicity, immunotolerance, sequence similarity, the low-similarity theory.
Graphical Abstract
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Analytical Chemistry
Current Computer-Aided Drug Design
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Related Books
test ebook
2-Deoxy-D-Glucose: Chemistry and Biology
Chiral Ionic Liquids: Applications in Chemistry and Technology
Anthocyanins: Pharmacology and Nutraceutical Importance
Therapeutic Insights into Herbal Medicine through the Use of Phytomolecules
Computer-Aided Drug Discovery Methods: A Brief Introduction
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Biochar - Solid Carbon for Sustainable Agriculture
DFT-Based Studies On Atomic Clusters
20